Immunic Inc.

IMUX | NASDAQ

Price Alert Chart Builder DCF Calculator

$10.83

+$0.21 (+1.98%)

At close: Sep 21, 2026, 4:00 PM ET

$11.14

+$0.31 (+2.85%)

Pre-market: Sep 22, 2026, 7:26 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+1.98%

(1D)

Rating

Updated: Sep 10, 2026

21.5

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $147.52M

1D Range

10.55 11.03

52W Range

5.06 17.43

Valuation (TTM)

PE -2.26

PB 1.16

EV/EBITDA 0.06

Valuation (NTM)

Forward PE N/A

Forward PEG 0.07

Price Target $22.13

Cash Flow

FCF Yield -59.7%

SBC Adj. FCF Yield -70.7%

SBC Impact -18.4%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y N/A | N/A

Dil EPS 3Y | 5Y 52.1% | 40.1%

FCF 3Y | 5Y -9.1% | -5.3%

Returns

ROA -70.1%

ROE -157.9%

ROIC -92.0%

Financial Health

Net Cash

$155.1M

Current Ratio 5.05

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditi...

Sector Healthcare

Industry Biotechnology

Employees 100

IPO Date Apr 16, 2014

Website imux.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$20.50

Upside

+89.29%

Buy (3)

Hold (1)

Sell (0)

Analyst Details ➞